Power of compounding intravitreal Bevacizumab - Experience from a tertiary eye care hospital
Indian J Ophthalmol
;
2022 May; 70(5): 1869
Artículo
| IMSEAR
| ID: sea-224340
ABSTRACT
Background:
Bevacizumab vials that are commercially available are fractionated into smaller quantities into the form of pre?filled syringes in a sterile and aseptic laboratory setting.Purpose:
To share the long term experience of aliquoting of bevacizumab injections in a tertiary eye care center in India. Synopsis Compounding of bevacizumab was found to be a cost?effective and sustainable practice that has benefited more patients with an affordable cost, while maintaining high levels of quality. Highlights Compounding of bevacizumab, when done with aseptic precautions can be a safe and cost?effective practice, the benefits of which can be passed on to needful patients.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Revista:
Indian J Ophthalmol
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS